{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:51:31Z","timestamp":1775843491649,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10147-025-02923-x","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:44:00Z","timestamp":1765298640000},"page":"227-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is neoadjuvant therapy necessary for resectable pancreatic cancer? A review of randomized controlled trials to date: a narrative review"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2318-1129","authenticated-orcid":false,"given":"Hidetoshi","family":"Eguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"issue":"5","key":"2923_CR1","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1200\/JCO.2016.68.5081","volume":"35","author":"AA Mokdad","year":"2017","unstructured":"Mokdad AA, Minter RM, Zhu H et al (2017) Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol 35(5):515\u2013522. https:\/\/doi.org\/10.1200\/JCO.2016.68.5081","journal-title":"J Clin Oncol"},{"issue":"1","key":"2923_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00066-014-0737-7","volume":"191","author":"H Golcher","year":"2015","unstructured":"Golcher H, Brunner TB, Witzigmann H et al (2015) Neoadjuvant chemoradiation therapy with gemcitabine\/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol 191(1):7\u201316. https:\/\/doi.org\/10.1007\/s00066-014-0737-7","journal-title":"Strahlenther Onkol"},{"issue":"10","key":"2923_CR3","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1007\/s11605-015-2890-4","volume":"19","author":"R Casadei","year":"2015","unstructured":"Casadei R, Di Marco M, Ricci C et al (2015) Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg 19(10):1802\u20131812. https:\/\/doi.org\/10.1007\/s11605-015-2890-4","journal-title":"J Gastrointest Surg"},{"issue":"6","key":"2923_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S2468-1253(18)30081-5","volume":"3","author":"M Reni","year":"2018","unstructured":"Reni M, Balzano G, Zanon S et al (2018) Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2\u20133 trial. Lancet Gastroenterol Hepatol 3(6):413\u2013423. https:\/\/doi.org\/10.1016\/S2468-1253(18)30081-5","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"16","key":"2923_CR5","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/JCO.19.02274","volume":"38","author":"E Versteijne","year":"2020","unstructured":"Versteijne E, Suker M, Groothuis K et al (2020) Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol 38(16):1763\u20131773. https:\/\/doi.org\/10.1200\/JCO.19.02274","journal-title":"J Clin Oncol"},{"issue":"11","key":"2923_CR6","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne E, van Dam JL, Suker M et al (2022) Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol 40(11):1220\u20131230. https:\/\/doi.org\/10.1200\/JCO.21.02233","journal-title":"J Clin Oncol"},{"issue":"1","key":"2923_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.annonc.2022.09.161","volume":"34","author":"T Seufferlein","year":"2023","unstructured":"Seufferlein T, Uhl W, Kornmann M et al (2023) Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)\u2014a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol 34(1):91\u2013100. https:\/\/doi.org\/10.1016\/j.annonc.2022.09.161","journal-title":"Ann Oncol"},{"issue":"3","key":"2923_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","volume":"9","author":"KJ Labori","year":"2024","unstructured":"Labori KJ, Bratlie SO, Andersson B et al (2024) Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 9(3):205\u2013217. https:\/\/doi.org\/10.1016\/S2468-1253(23)00405-3","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"17","key":"2923_CR9","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1200\/JCO-24-01378","volume":"43","author":"L Schwarz","year":"2025","unstructured":"Schwarz L, Bachet JB, Meurisse A et al (2025) Neoadjuvant FOLF(IRIN)OX chemotherapy for resectable pancreatic adenocarcinoma: a multicenter randomized noncomparative phase II trial (PANACHE01 FRENCH08 PRODIGE48 study). J Clin Oncol 43(17):1984\u20131996. https:\/\/doi.org\/10.1200\/JCO-24-01378","journal-title":"J Clin Oncol"},{"issue":"4","key":"2923_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1200\/JCO.2019.37.4_suppl.189","volume":"37","author":"M Unno","year":"2019","unstructured":"Unno M, Motoi F, Matsuyama Y et al (2019) Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP-05). J Clin Oncol 37(4):189","journal-title":"J Clin Oncol"},{"issue":"15","key":"2923_CR11","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1200\/JCO.2019.37.15_suppl.4126","volume":"37","author":"S Satoi","year":"2019","unstructured":"Satoi S, Unno M, Motoi F et al (2019) The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II\/III trial; Prep-02\/JSAP-05). J Clin Oncol 37(15):4126","journal-title":"J Clin Oncol"},{"key":"2923_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006730","author":"M Unno","year":"2025","unstructured":"Unno M, Motoi F, Matsuyama Y et al (2025) Neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer: results of the randomized phase II\/III Prep-02\/JSAP05 trial. Ann Surg. https:\/\/doi.org\/10.1097\/SLA.0000000000006730","journal-title":"Ann Surg"},{"issue":"11","key":"2923_CR13","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/jhbp.1353","volume":"30","author":"T Sugiura","year":"2023","unstructured":"Sugiura T, Toyama H, Fukutomi A et al (2023) Randomized phase trial of chemoradiotherapy with S\u20101 versus combination chemotherapy with gemcitabine and S\u20101 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04). J Hepatobiliary Pancreat Sci 30(11):1249\u20131260. https:\/\/doi.org\/10.1002\/jhbp.1353","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"7","key":"2923_CR14","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1245\/s10434-024-15199-8","volume":"31","author":"D Yamada","year":"2024","unstructured":"Yamada D, Kobayashi S, Takahashi H et al (2024) Results of a randomized clinical study of gemcitabine plus Nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (RCT, CSGO-HBP-015). Ann Surg Oncol 31(7):4621\u20134633. https:\/\/doi.org\/10.1245\/s10434-024-15199-8","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2923_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11141-5","volume":"23","author":"JL van Dam","year":"2023","unstructured":"van Dam JL, Verkolf EMM, Dekker EN et al (2023) Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. BMC Cancer 23(1):728. https:\/\/doi.org\/10.1186\/s12885-023-11141-5","journal-title":"BMC Cancer"},{"issue":"10","key":"2923_CR16","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1245\/s10434-024-15817-5","volume":"31","author":"AV Eade","year":"2024","unstructured":"Eade AV, Friedman LR, Larrain C et al (2024) Alliance A021806: a phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer. Ann Surg Oncol 31(10):6373\u20136374. https:\/\/doi.org\/10.1245\/s10434-024-15817-5","journal-title":"Ann Surg Oncol"},{"key":"2923_CR17","unstructured":"Unno M, Aoki S. JCOG2101C: Preoperative therapy of GS vs. GnP randomized trial for resectable pancreatic cancer in geriatric patients (PRESTIGE). https:\/\/jrct.mhlw.go.jp\/en-latest-detail\/jRCTs031220351"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02923-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02923-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02923-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T04:07:51Z","timestamp":1769486871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02923-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2923"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02923-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}